| Name | Title | Contact Details |
|---|
Vium is the first company to create a living informatics platform for preclinical in vivo drug research.
Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics.
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.
The CereVasc eShunt™ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.